A Phase I Trial of BLU-263 in Healthy Volunteers
Latest Information Update: 05 Aug 2021
At a glance
- Drugs Elenestinib (Primary)
- Indications Systemic mastocytosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Blueprint Medicines
Most Recent Events
- 17 Jun 2021 Results assessing safety, tolerability, and pharmacokinetics of BLU-263 in normal healthy volunteers, presented at the 26th Congress of the European Haematology Association.
- 11 Apr 2021 According to a Blueprint Medicines media release, data from this study was presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.
- 11 Apr 2021 Results published in the Blueprint Medicines media release.